0
Cardiothoracic Surgery |

Morbidity Profiles Following Thoracoscopic Segmentectomy and Lobectomy for Clinical Stage I Non-small Cell Lung Cancer

Nikiforos Ballian*, MBBS; Matthew Schuchert, MD; David Wilson, MD; Daniel Normolle, MD; Joshua Landreneau, MD; Andre Pitanga, MD; Jamilly Gomes, MD; Felipe Franca, MD; Ghulam Abbas, MD; Omar Awais, MD; Neil Christie, MD; James Luketich, MD; Rodney Landreneau, MD
Author and Funding Information

University of Pittsburgh, Pittsburgh, PA


Chest. 2012;142(4_MeetingAbstracts):48A. doi:10.1378/chest.1390684
Text Size: A A A
Published online

Abstract

SESSION TYPE: Thoracic Surgery II

PRESENTED ON: Tuesday, October 23, 2012 at 04:30 PM - 05:45 PM

PURPOSE: Sublobar resection is re-emerging as an alternative to lobectomy in the management of small, early-stage non-small cell lung cancers. However, the potential advantages of thoracoscopic segmentectomy compared to thoracoscopic lobectomy remained undefined. We hypothesize that thoracoscopic segmentectomy has comparable peri-operative morbidity profiles when compared to thoracoscopic lobectomy in patients undergoing lung resection for clinical stage I non-small cell lung cancer.

METHODS: Patients undergoing thoracoscopic segmentectomy (n=163) or lobectomy (n=190) for clinical stage I non-small cell lung cancer were identified from a prospectively maintained single-institution database. All patients had histologically confirmed non-small cell lung cancer resected thoracoscopically. Primary outcomes included morbidity, mortality, length of hospital stay, readmission rate, as well as disease-free survival. Comparisons were performed with the Student’s t-test and Fisher’s exact test. Actuarial estimates of recurrence-free survival were performed utilizing the Kaplan-Maier method, with significance being assessed via the log rank test.

RESULTS: There were no differences in age and gender distribution between patients undergoing lobectomy and segmentectomy. Patients undergoing lobectomy had larger tumors (mean 2.5 cm vs. 1.9 cm, p<0.001). Overall morbidity (36.8% vs. 31.9%), mortality (0.5% vs. 0.6%), length of hospital stay (5 vs. 6 days), 30-day readmission rate (7.9% vs. 8.6%), as well as recurrence-free survival (58 vs. 53%) were similar between groups. The most common complication was atrial fibrillation (Segment=6.7%; Lobe=4.7%, p=0.49). The most common major complication was pneumonia (Segment=11.0%; Lobe=12.1%, p=0.87). There were no significant differences in morbidity when comparing individual segments to their corresponding lobes. Similarly, there was no significant difference in morbidity profile when comparing upper lobe vs. lower lobe resections.

CONCLUSIONS: Thoracoscopic segmentectomy has comparable perioperative outcomes and morbidity profiles when compared to thoracoscopic lobectomy in the setting of stage I non-small cell lung cancer. These findings will need to be validated by prospective randomized comparisons (CALGB 140503).

CLINICAL IMPLICATIONS: Thoracoscopic segmentectomy can be performed with acceptable oncologic and morbidity outcomes for clinical stage I non-small cell lung cancer.

DISCLOSURE: The following authors have nothing to disclose: Nikiforos Ballian, Matthew Schuchert, David Wilson, Daniel Normolle, Joshua Landreneau, Andre Pitanga, Jamilly Gomes, Felipe Franca, Ghulam Abbas, Omar Awais, Neil Christie, James Luketich, Rodney Landreneau

No Product/Research Disclosure Information

University of Pittsburgh, Pittsburgh, PA

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Segmentectomy for lung cancer. Semin Thorac Cardiovasc Surg 2010;22(3):244-9.
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543